Αρχική World News 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers

2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers

In the annual Research Round Up series, Cancer.Net Editorial Board members answer the questions, “What was the most exciting or practice-changing research in your field presented at the 2021 ASCO Annual Meeting, and what does it mean for people with cancer?” In this webinar, Cancer.Net Specialty Editors Neeraj Agarwal, MD; Petros Grivas, MD, PhD; Tian Zhang, MD, MHS; and Timothy Gilligan, MD, FASCO, discuss new and ongoing research in prostate cancer, bladder cancer, kidney cancer, and testicular cancer.

  • A Medicare database analysis evaluated how often standard of care therapies for metastatic castration-sensitive prostate cancer were being used in real-world treatment from 2009 to 2018, particularly among racial minorities. [3:07]

  • Results from the TITAN phase III clinical trial, which showed whether adding apalutamide (Erleada) to hormonal therapy impacted quality of life in people with metastatic castration-sensitive prostate cancer. [8:14]

  • Findings from the VISION phase III clinical trial, which was studying whether adding a new type of radiation therapy to the standard of care for people with metastatic castration-resistant prostate cancer stopped cancer growth and helped them live longer. [11:15]

  • An analysis of the subgroups from the JAVELIN Bladder 100 phase III clinical trial evaluated whether adding maintenance immunotherapy using avelumab (Bavencio) to supportive care after chemotherapy for people with advanced bladder cancer helped all patients or only certain subgroups of patients live longer. [14:57]

  • Updated results after 5 years of follow-up from the KEYNOTE-052 phase II clinical trial, which showed whether treatment with the immunotherapy pembrolizumab (Keytruda) helped shrink the tumors of people with advanced bladder cancer who could not receive cisplatin-based chemotherapy. [19:43]

  • Updated results after 5 years of follow-up from the KEYNOTE-045 phase III clinical trial, which evaluated whether pembrolizumab helped people live longer if they have recurrent, advanced bladder cancer that progressed after platinum-based chemotherapy. [24:15]

  • Findings from the KEYNOTE-564 phase III clinical trial, which was studying whether pembrolizumab delayed recurrence if it was given to people with high-risk clear cell kidney cancer following surgery to remove the tumor. [26:22]

  • Updated results after 3 and a half years of follow-up from the KEYNOTE-426 phase III clinical trial, which was evaluating whether the combination of pembrolizumab and the targeted therapy axitinib (Inlyta) stopped cancer growth for people with advanced clear cell kidney cancer and helped them live longer. [28:11]

  • An analysis from the CLEAR phase III clinical trial showed whether treatment with the targeted therapy lenvatinib (Lenvima) and pembrolizumab improved quality of life for people with advanced kidney cancer compared with treatment with sunitinib (Sutent) alone. [29:48]

  • Results from a phase I/II clinical trial testing whether treating people with MET-driven, metastatic papillary kidney cancer using a combination of the targeted therapies savolitinib (AZD6094, HMPL-504, volitinib) and durvalumab (Imfinzi) helped shrink the cancer. [32:18]

  • An analysis of cancer registry data in Norway showed that people who are cured of testicular cancer using radiation therapy and/or chemotherapy had a higher risk of dying from causes other than testicular cancer compared with individuals in the general population. [33:28]

  • Results from the SEMS phase II clinical trial, which was evaluating whether surgery using retroperitoneal lymph node dissection (RPLND) could be an alternative to chemotherapy or radiation therapy for people with early metastatic seminoma. [36:52]

Dr. Agarwal is the senior director of clinical research innovation at the Huntsman Cancer Institute at the University of Utah and is a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Grivas is the clinical director of the Genitourinary Cancers Program at University of Washington Medicine, an associate member of the clinical research division at the Fred Hutchinson Cancer Research Center, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Zhang is an associate professor of medicine at Duke University School of Medicine, a medical oncologist at Duke Cancer Institute, and a Cancer.Net Specialty Editor for Genitourinary Cancers. Dr. Gilligan is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute and a Cancer.Net Specialty Editor for Genitourinary Cancers.

Disclosure information for this webinar’s speakers can be found in their individual biographies, which are linked in the paragraph above.

Cancer.Net podcasts are edited for length and content.

Was this webinar useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded webinar can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...